Q-omics provides the consensus-scored CD300E profile across patient tissues and cancer cell-line models. CD300E expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CD300E is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CD300E RNA expression shows 22,498 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, KIRC, and GBM as cancer lineages where CD300E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD300E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD300E survival associations across molecular data types. CD300E RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD300E RNA expression–survival associations across cancer types. High CD300E expression shows unfavorable associations in THCA, KIRP, UCEC, LUSC and LAML, but favorable associations in SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for CD300E RNA expression.
This table summarizes CD300E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD300E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD300E shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in KIRC, HNSC and COAD. The KIRC box plot shows higher CD300E RNA expression in tumor versus normal tissue (log2 FC = +1.204, t-test p < 0.001).
This table shows molecular features associated with CD300E in patient tissues and cancer cell lines. In patient samples, CD300E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD300E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
